Purified LH

Abstract

Recombinant human luteinizing hormone (LH) having a specific bioactivity of from 20,522 to 31,229 IU / mg and obtainable from a process for the purification of recombinant LH from a sample of crude recombinant LH in the supernatant of CHO cells which comprises the combined use of ion-exchange chromatography and reverse phase HPLC. The ion-exchange chromatography and the reverse phase HPLC are performed twice and the final use of a gel permeation column allows the purification from any residual traces of contaminants. The recombinant LH can be formulated into a pharmaceutical composition and used for treating a fertility disorder.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] The present application is a division of 10 / 204,554, which is a 371 national stage application of PCT EP01 / 00666, filed Jan. 22, 2001. The entire content of both applications are incorporated herein by reference.FIELD OF INVENTION [0002] The present invention relates to a process for the purification of Luteinising Hormone (LH), in particular the purification of recombinant LH (r-LH) from a sample of crude recombinant LH, comprising the combined use of ion-exchange chromatography and reverse phase HPLC. Luteinising Hormone (LH) is a gonadotropin secreted by the anterior lobe of the pituitary together with another gonadotropin, follicle-stimulating hormone (FSH). These hormones are heterodimers consisting of non-covalently bound α and β subunits. [0003] These gonadotropins stimulate the normal functioning of the gonads and the secretion of sex hormones in both men and women. In women, follicle-stimulating hormone stimulates the developme...

AI Technical Summary

Benefits of technology

[0012] It is, therefore, an object of the present invention to provide a process for purification of LH from a sample comprising the combined use of ion-exchange chromatography and reverse phase HPLC. The process comprises the steps of subjecting the sample (if necessary concentrated) to ion-exchange chromatography and subjecting the eluate to reverse phase HPLC. A further step of applying the eluate to a gel permeation column may additionally be carried out.

[0023] It is a further object of the present invention to provide a pharmaceutical composition comprising a therapeutically effective amount of the recombinant LH as prepared by the recombinant process as described above, together with suitable excipients, such as sucrose, necessary for the stabilisation of the lyophilised product. The pharmaceutical composition of the recombinant LH is particularity suitable for subcutaneous administration.

Problems solved by technology

Ion-exchange chromatrography has been used for the isolation of these hormones, however, this method appears to have several interrelated problems caused by the considerable charge heterogeneity of LH in pituitary tissue.

First, because these glycoproteins and FSH have overlapping charges, their complete separation is difficult and laborious.

Secondly, the purification of these hormones as single fractions may be difficult (Stockell Hartree, A., Thomas, M., Furnival, B. E., Burns, T. W. & Langley, P. Thyroid-stimulating and lipolytic activities of purified preparation s of human thyroid-stimulating hormone.

Selective purification will further complicate the characterization of these heterogeneous forms, including the structural analysis of their carbohydrate components.

Variation in the content of anionic oligosaccharides that contain sialyl and sulphate groups may be the major cause of charge heterogeneity in LH.

Images